



DECLARATION OF CHARISSE M. LODER, M.D.

DOWNLOAD LEGAL DOCUMENT

8. My involvement in the process of trying to make Mifeprex available at the University of Michigan began when I arrived at the University six years ago, in 2015. But conversations surrounding Mifeprex at the University of Michigan began seven years ago, in 2014. As of 2014, the only patients who could access mifepristone through the University of Michigan were those seeking treatment for Cushing's syndrome: University clinicians were able to prescribe mifepristone under the brand name Korlym, and the patients filled those prescriptions through a mail-order pharmacy. However, patients in need of mifepristone under the brand name Mifeprex, for reproductive health care, could not access the medication through any University provider.

9. As a first step, I had to get approval to add Mifeprex to the University's drug formulary from the University's Pharmacy and Therapeutics Committee ("the Committee"), which is composed of pharmacists and physicians from a variety of clinical specialties. As discussed above, I was not the first physician to attempt to do so; in 2014, other physicians had participated in multiple meetings with the Committee during which they advocated for adding Mifeprex to the formulary. Ultimately, these conversations stalled because those physicians were unable to invest the immense amounts of time required to move this process forward.

10. Between 2015 and 2016, I participated in approximately four Committee meetings relating to Mifeprex. To assist in the Committee's evaluation of Mifeprex, the Committee asked me and my colleagues to provide literature on Mifeprex's safety and indications for use, which we did. These meetings were each about an hour long, and I individually spent at least 20 additional hours researching and preparing presentations about Mifeprex's safety and efficacy, as well as

and preparing presentations about mifepristone's safety and efficacy, as well as

writing guidelines for its use.

11. Finally, in 2016, the Committee approved Mifepristone for the University

Related Issues: [Federal Abortion Legislation](#), [Abortion](#), [Reproductive Freedom](#)

RELATED STORIES



Chelius v.
Becerra
OCTOBER 3, 2017

STAY INFORMED

JOIN OUR NEWSLETTER